Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2026 16:30 ET | Source: Custom Market Insights

Global Compression Garments and Stockings Market Size/Share Worth USD 5.10 Billion by 2035 at a 4.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

Austin, TX, USA, April 28, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Compression Garments and Stockings Market Size, Trends and Insights By Product...
April 24, 2026 16:00 ET | Source: Compass Therapeutics

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical...
March 25, 2026 11:11 ET | Source: Faruqi & Faruqi LLP

NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or...
March 25, 2026 10:00 ET | Source: Eascra Biotech

Eascra Biotech Takes First Place at TechConnect Bio in Space Innovation Challenge

Eascra Biotech, a nanomedicine startup, has won first place at the TechConnect Bio in Space Innovation Challenge
March 06, 2026 17:01 ET | Source: Faruqi & Faruqi LLP

NKTR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or...
February 24, 2026 09:00 ET | Source: Human Continuum Inc.

Human Continuum Appoints Dr. Michael Milligan, MD, MBA, as its Chief Medical Officer to Oversee Innovative Applications for Next-Generation Extracellular Vesicle Therapeutics

New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
February 19, 2026 03:30 ET | Source: Custom Market Insights

Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Global ALS therapeutics market is expected to grow from USD 1.05B in 2025 to USD 1.96B by 2034 at 11.5% CAGR, driven by new therapies and rising worldwide.
February 16, 2026 10:00 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Global Oligonucleotide Therapeutics Market Set to Surge to USD 17.70 Billion by 2030 | MarketsandMarkets™

Delray Beach, FL, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Strategic investments in ASO and siRNA platforms, coupled with breakthrough delivery technologies, position oligonucleotide therapeutics as...
January 30, 2026 08:00 ET | Source: Alps Group Inc

Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy

KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...
January 22, 2026 09:00 ET | Source: Human Continuum Inc.

Human Continuum Appoints Dr. Omar Khalid Sial, Ph.D., as its Chief Scientific Officer to Spearhead the Development of Innovative Extracellular Vesicle Topical Formulations and Advanced Biologic Therapies

New York, N.Y., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...